References
- Dodd S. Current insights in the placebo and nocebo phenomena. Clin Ther. 2017;39(3):456–457.
- Dodd S, Schacht A, Kelin K, et al. Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials. J Clin Psychiatry. 2015;76(6):702–711.
- Wahlbeck K, Tuunainen A, Ahokas A, et al. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl). 2001;155:230–233.
- Rief W, Nestoriuc Y, Von Lilienfeld-Toal A, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials. Drug Saf. 2009;32:1041–1056.
- Hwang SS, Jung DC, Ahn YM, et al. The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia. Int Clin Psychopharmacol. 2010;25:83–90.
- Palermo S, Giovannelli F, Bartoli M, et al. Are patients with schizophrenia spectrum disorders more prone to manifest nocebo-like-effects? a meta-analysis of adverse events in placebo groups of double-blind antipsychotic trials. Front Pharmacol. 2019;10:502.
- Brambilla P, Cipriani A, Hotopf M, et al. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005;38:69–77.
- Amanzio M, Corazzini LL, Vase L, et al. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain. 2009;146:261–269.
- Dodd S, Walker AJ, Brnabic AJM, et al. Incidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorder. Bipolar Disord. 2019;21(2):142–150.
- Amanzio M, Palermo S, Skyt I, et al. Lessons learned from nocebo effects in clinical trials for pain conditions and neurodegenerative disorders. J Clin Psychopharmacol. 2016;36(5):475–482.
- Amanzio M. Do we need a new procedure for the assessment of adverse events in anti-migraine clinical trials? Recent Pat CNS Drug Discov. 2011;6(1):41–47.
- De la Cruz M, Hui D, Parsons HA, et al. Placebo and nocebo effects in randomized double-blind control trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer. 2010;116:766–774.
- Barsky AJ, Saintfort R, Rogers MP, et al. Nonspecific medication side effects and the nocebo phenomenon. J Am Med Assoc. 2002;287:622–627.
- Amanzio M, Benedetti F, Vase L. A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment. Int Psychogeriatr. 2012;24:698–707.
- Kim JH, Lee BC, Park HJ, et al. Subjective emotional experience and cognitive impairment in drug-induced akathisia. Comp Psychiatry. 2002;43:456–462.
- Hwang SS, Chang JS, Lee KY, et al. The causal model of insight in schizophrenia based on the positive and negative syndrome scale factors and the structural equation modeling. J Nerv Ment Dis. 2009;197:79–84.
- Enck P, Bingel U, Schedlowski M, et al. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov. 2013;12:191–204.
- von Blanckenburg P, Schuricht F, Albert US, et al. Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer. 2013;13:426.
- Mitsikostas DD, Deligianni CI. Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation. Neurol Sci. 2015;36(3):379–381.